2026 Interim Report
Filed with HKEX · Stock code 1541 · · 63 pages · English
ImmuneOnco Biopharmaceuticals (Shanghai) Inc on 6ix
Earlier from ImmuneOnco Biopharmaceuticals (Shanghai)
- ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
- Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
- Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Later from ImmuneOnco Biopharmaceuticals (Shanghai)
- Voluntary announcement - completion of capital Increase of a subsidiary
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September, 2026
- Proposed change of auditor
Follow ImmuneOnco Biopharmaceuticals (Shanghai) into a list and get an email when it puts out news.
Follow ImmuneOnco Biopharmaceuticals (Shanghai)